Drug Trial Radar · NCT06615193
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Aug 12, 2024
Primary completion
Jun 24, 2026
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
Conditions
- Advanced Solid Tumors
- Refractory Lymphoma
- Relapsed Hematologic Malignancy
Interventions
HDM2005Drug
HDM2005 will be administered via IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicity (DLT) events (for dose escalation phase)Time frame: up to 21 days following first dose
- Incident and severity of adverse events(for dose escalation phase)Time frame: Until 28 days after the last dose or initiation of a new antineoplastic therapy, whichever occurs first
- Objective Response Rate (ORR)(for dose expansion phase)Time frame: Until withdrawal of consent, loss to follow-up, initiation of other new antineoplastic therapy, end of study, or study termination by the sponsor, whichever occurs first (up to approximately 3.5 years)
- Recommended Phase 2 Dose (RP2D) (for dose expansion phase)Time frame: Approximately 3.5 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
The Institute of Hematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences
Tianjing, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital Of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.